Your browser does not support the NLM PubReader view.

Go to this page to see a list of supporting browsers.

Modeling α-Synuclein Propagation with Preformed Fibril Injections

Article information

J Mov Disord. 2020;13(1):77-79
Publication date (electronic) : 2019 October 14
doi : https://doi.org/10.14802/jmd.19046.e
Hyun Kyung Chung1, Hoang-Anh Ho2, Dayana Pérez-Acuña1, Seung-Jae Lee1,3
1Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea
2Interdisciplinary Program in Neuroscience, College of Natural Sciences, Seoul National University, Seoul, Korea
3Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea

J Mov Disord 2019;12(3):139-151.

DOI: https://doi.org/10.14802/jmd.19046

In the original version of Table 1 associated with the review article “Modeling α-Synuclein Propagation with Preformed Fibril Injections”, the “amount of PFF injected” for the Rey et al. 2018 paper should be “0.8 μg of 5 mg/ml” instead of “8 μg 1 mg/ml”. The injection site mentioned in the “amount of PFFs injected” for Breid et al. 2016 paper should be “intraperitoneal” instead of “intramuscular”. The “amount of PFFs injected” for the Manfredsson et al. 2018 paper should be “6×5 μl” instead of “5 μg”. Additional information on the concentration of PFFs was added for Breid et al. 2016 paper and Durante et al. 2019 paper, being “1 μg/μl” and “1 mg/ml”, respectively.

Injection methodologies from recent studies

In the first paragraph of the “SYNUCLEINOPATHIES IN PERIPHERAL PFF INJECTION MODELS” section, we included the description olfactory bulb injection. However, this content belongs to the “SYNUCLEINOPATHIES IN INTRACEREBRAL PFF INJECTION MODELS” section.

Article information Continued

Copyright © 2020 The Korean Movement Disorder Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1.

Injection methodologies from recent studies

Author Year Injection site Duration/Time point Model Amount of PFFs injected
Luk et al. [20] 2012 Somatosensory cortex and dorsal neostriatum 30 and 90 days post injection (p.i) M83 mice maintained on a C57BL/C3H background, α-syn -/- mice maintained on a C57BL/6 background 5 μg of 5 mg/mL human α-syn1-120Myc or WT full-length human α-syn per brain
Luk et al. [18] 2012 Striatum 30, 90, and 180 days p.i C57BL6/C3H F1, C57BL6/SJL F1, and CD1 mice 5 μg of 5 mg/mL full-length WT mouse α-syn per hemisphere
Masuda-Suzukake et al. [40] 2013 Substantia nigra 15 months p.i 4- to 6-month-old female C57BL/6J mice 10 µg of mouse or human α-syn PFFs
Guo et al. [60] 2013 Hippocampus 3, 6, and 9 months p.i 2- to 3-month-old PS19 mice or C57BL6/C3H F1 mice 5 μg of PFFs
Sacino et al. [49] 2014 Hippocampus 1, 2, and 4 months p.i 2-month-old M83 mice and M20 mice 2 μL of 2 mg/mL hfib 21–140 or Δ71–82 α-syn
Sacino et al. [27] 2014 Intramuscular (biceps femoris) 4, 8, and 12 months p.i 2-month-old M83 mice and M20 mice 10 μg of mouse PFFs, human 21–140 α-syn PFFs or Δ71–82 α-syn
Paumier et al. [48] 2015 Striatum 30, 60, and 180 days p.i Adult male Sprague-Dawley rats 8 μg of mouse or human α-syn PFFs
Osterberg et al. [39] 2015 Cortex 2, 3, and 4 months p.i 2- to 3-month-old α-syn-GFP mice 2.5 µL of 2 mg/mL mouse WT α-syn PFFs
Peelaerts et al. [57] 2015 Substantia nigra 4 months p.i Female Wistar rats 2 µL of 5 µg/µL α-syn PFFs (total of 10 µg)
Breid et al. [30] 2016 Peritoneum, tongue Up to 420 days p.i Tg (M83+/−:Gfap-luc+/−) and (Gfap-luc+/−) mice 5 μl (intraglossal) or 50 μl (intraperitoneal) of 1 ug/ul sonicated α-syn PFFs
Kim et al. [59] 2016 Striatum 3 and 6 months p.i 3-month-old C57BL/6J mice 5 μL of 10 μg/μL recombinant α-syn monomer, 2 μg/μL LPS(−) fibril seed, and 2 μg/μL LPS(+) fibril seed
Thakur et al. [45] 2017 Substantia nigra, ventral tegmental area 10 days p.i Female Sprague-Dawley rats 2.5 μL of full-length recombinant human α-syn PFFs (10 μg total) per site
Karampetsou, et al. [21] 2017 Striatum 60 days p.i 2- to 4-month-old male and female wild-type C57BL6/C3H mice and α-Syn-/- mice (C57BL6/JOlaHsd mice) 4.25 μg (4 μL) of three different types of human recombinant fibrillar α-syn
Abdelmotilib et al. [35] 2017 Striatum 6 months p.i 8- to 10-week-old mice and rats 10 μg (mice) or 20 μg (rats) of mouse or human α-syn PFFs
Blumenstock et al. [43] 2017 Dorsal striatum 30, 60, and 90 days p.i; 5 and 9 months p.i 2-month-old mice 5 μL (25 μg) of mouse α-syn PFFs
Sorrentino et al. [56] 2017 IC or CPu 4–5 months p.i 4-month-old M20 non-Tg (NTG) mice 2 μL of 2 mg/mL human or mouse WT α-syn PFFs
Harms et al. [63] 2017 Substantia nigra 1, 3, and 6 months p.i 8- to 10-week old Sprague-Dawley rats 8 μg of mouse α-syn PFFs
Shimozawa et al. [50] 2017 Caudate and putamen 3 months p.i 26-month-old marmosets 50 μL aliquots of 4 mg/mL mouse α-syn PFFs
Okuzumi et al. [44] 2018 Striatum 1 week pi, 0.75, 1.5, 3, and 6 months p.i 2- to 3-month-old C57BL/6J mice 5 μg/2.5 μL of recombinant mouse or human α-syn PFFs
Rey et al. [29] 2018 Olfactory bulb 1, 2, 3, 6, 9, 12, 18, and 23 months p.i 3-month-old female C57BL/6J mice 0.8 μl of 5 mg/ml WT mouse or human α-syn PFFs
Uemura et al. [28] 2018 Mouse gastric wall 45 days p.i 2-month-old male C57BL/6J mice 3 μL of 2 μg/μL mouse α-syn PFFs
Duffy et al. [47] 2018 Striatum 6 months p.i 2-month-old male Fischer mice 2 μL of 2 μg/μL mouse α-syn PFFs (unilateral)
Sorrentino et al. [42] 2018 Muscle 1, 2, 3, and 4 months p.i 2-month-old M83+/- mice 2,5, or 10 μg of mouse α-syn fibrils
Milanese et al. [41] 2018 Striatum 4 months p.i C57BL/6 mice 5 μg (2.5 μL) of human α-syn PFFs
Terada et al. [46] 2018 Striatum 3 months p.i 10-week-old C57BL/6J mice 5 μL (150 μM) of human WT
Milanese et al. [41] 2018 Striatum 4 months p.i C57BL/6 mice 5 μg (2.5 μL) of human α-syn PFFs
Terada et al. [46] 2018 Striatum 3 months p.i 10-week-old C57BL/6J mice 5 μL (150 μM) of human WT or truncated α-syn PFFs
Ayers et al. [54] 2018 Sciatic nerve (unilateral) 1, 2, and 4 months p.i and end-stage M83 and M20 mice 2 μL of 2 mg/mL mouse WT or human Δ71–82 α-syn PFFs
Manfredsson et al. [55] 2018 Enteric neurons of the descending colon 1, 6, and 12 months p.i Young adult male Sprague-Dawley rats 6×5 µl of 2 μg/μl mouse or human α-syn PFFs
Manfredsson et al. [55] 2018 Colon and stomach 12 months p.i Non-human primates (Macaca fascicularis) 10 injections of 10 µL (2 µg/µL)
Peralta Ramos et al. [68] 2019 Vein 12 hours p.i 2-month-old C57BL/6 mice 5 μg of Atto 488-labeled α-syn fibrils or ribbons
Durante et al. [77] 2019 Striatum 6, 7 weeks p.i Male Wistar rats 1 µL of 1 mg/ml human α-syn PFFs per site

The table describes the sites of preformed fibril (PFF) injection, the ages of the animals, the amount of seed, and the duration or time points sample analysis used in the experiments. WT: wild type, GFP: green fluorescent protein, LPS: lipopolysaccharide, IC: inferior colliculus, CPu: caudate putamen, NTG: non-Tg.